This study investigates how well different treatments work for patients with a type of cancer called anaplastic large cell lymphoma (ALCL). ALCL is a cancer that affects the lymph nodes and is characterized by certain markers on the cancer cells, like CD30 and ALK. The study is testing two treatment arms: one uses an investigational medication combined with standard chemotherapy, and the other uses a different investigational medication with chemotherapy. The goal is to see how well these treatments work and how patients tolerate them.

Participants in the study will receive either the investigational medication brentuximab vedotin or crizotinib, each combined with chemotherapy. The study will monitor how patients respond to these treatments and any side effects they experience. Brentuximab vedotin and crizotinib are investigational medications, which means they are not yet approved for general use. The study will compare the results to past data to see if these new combinations improve patient outcomes.

• Who can participate: This study is for patients newly diagnosed with ALCL, a type of lymphoma, who have stage II, III, or IV disease that is CD30 and ALK positive, with a life expectancy of at least 8 weeks.
• Study details: Participants will be assigned to one of two treatment arms and will receive either brentuximab vedotin or crizotinib along with chemotherapy. Brentuximab vedotin and crizotinib are investigational medications, meaning they are not yet approved for general use. Participants will not receive any payment for their involvement in the study.